<DOC>
	<DOCNO>NCT00854152</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I study evaluate safety , tolerability , pharmacokinetics escalate oral dos GDC-0980 administer patient incurable , locally advanced metastatic solid malignancy NHL progress failed respond least one prior regimen standard therapy .</brief_summary>
	<brief_title>A Study Evaluating GDC-0980 Administered Once Daily Patients With Refractory Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically document , incurable , locally advanced metastatic solid malignancy , NHL without leukemic phase , progress despite standard care therapy standard therapy proven clinical benefit ECOG performance status 0 1 screen Evaluable measurable disease per RECIST and/or follow : prostate cancer patient nonmeasurable disease eligible two rise prostatespecific antigen ( PSA ) level meet PSA Working Group criteria progression prior initiation study treatment ; ovarian cancer patient nonmeasurable disease eligible two rise CA125 level great ULN &gt; = 2 week apart prior initiation study treatment . Life expectancy &gt; =12 week Adequate hematologic organ function within 14 day initiation GDC0980 Documented willingness use effective mean contraception men woman participate study Leptomeningeal disease manifestation current malignancy History Type 1 2 diabetes mellitus require regular medication Grade &gt; = 2 hypercholesterolemia hypertriglyceridemia Ejection fraction &lt; 50 % LLN ( whichever high ) , determine echocardiogram MUGA scan DLCO &lt; 50 % predict value correct hemoglobin alveolar volume prior initiation GDC0980 Malabsorption syndrome condition would interfere enteral absorption Known untreated malignancy brain spinal cord , treat brain metastasis radiographically stable &gt; = 3 month Active congestive heart failure ventricular arrhythmia require medication Active infection require IV antibiotic Requirement daily supplemental oxygen Uncontrolled hypomagnesemia Hypercalcemia require continue use bisphosphonate therapy Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Uncontrolled ascites require frequent paracentesis Known HIV infection Any disease , active control pulmonary dysfunction , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug Significant traumatic injury within 4 week Day 1 Major surgical procedure within 4 week prior initiation GDC0980 For patient participate Stage 2 : Prior treatment PI3K inhibitor , mTOR inhibitor dual PI3K/mTOR inhibitor . For HNSCC patient , restriction applies PI3K inhibitor , mTOR inhibitor , dual PI3K/mTOR inhibitor use palliative setting . Treatment chemotherapy , hormonal therapy ( except hormone replacement therapy , oral contraceptive , GnRH agonists antagonist prostate cancer ) , immunotherapy , biologic therapy , radiation therapy ( except palliative radiation bony metastasis ) , herbal therapy cancer therapy within 3 week prior initiation GDC0980 Palliative radiation bony metastasis within 2 week prior initiation GDC0980 Need chronic corticosteroid therapy &gt; = 10 mg prednisone per day equivalent dose antiinflammatory corticosteroid immunosuppressant Treatment investigational agent within 4 week prior initiation GDC0980 Unresolved toxicity prior therapy except alopecia Grade 1 peripheral neuropathy Pregnancy lactation For patient participate DCEMRI assessment , contraindication MRI examination For patient advanced solid tumor NHL participate PPIeffect assessment : Known hypersensitivity rabeprazole , substitute benzimidazoles , component formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>Tumors</keyword>
	<keyword>Carcinogenic Tumors</keyword>
</DOC>